Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 26.92%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 37.65
2
The company has declared Positive results for the last 8 consecutive quarters
3
With ROCE of 46.34%, it has a attractive valuation with a 8.74 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 211,983 Million (Small Cap)
27.00
NA
0.00%
-0.15
28.13%
7.20
Revenue and Profits:
Net Sales:
24,983 Million
(Quarterly Results - May 2025)
Net Profit:
2,500 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-43.27%
0%
-43.27%
6 Months
-35.5%
0%
-35.5%
1 Year
-11.46%
0%
-11.46%
2 Years
33.17%
0%
33.17%
3 Years
18.3%
0%
18.3%
4 Years
-14.85%
0%
-14.85%
5 Years
-17.51%
0%
-17.51%
Jins Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.70%
EBIT Growth (5y)
4.46%
EBIT to Interest (avg)
44.88
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
2.26
Tax Ratio
31.40%
Dividend Payout Ratio
30.48%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
29.40%
ROE (avg)
15.81%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
7.15
EV to EBIT
18.85
EV to EBITDA
14.74
EV to Capital Employed
8.74
EV to Sales
2.19
PEG Ratio
0.19
Dividend Yield
NA
ROCE (Latest)
46.34%
ROE (Latest)
26.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : May 2015
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - May'25 - QoQ
May'25
Nov'24
Change(%)
Net Sales
24,983.00
21,056.00
18.65%
Operating Profit (PBDIT) excl Other Income
4,498.00
2,692.00
67.09%
Interest
20.00
35.00
-42.86%
Exceptional Items
-11.00
-1.00
-1,000.00%
Consolidate Net Profit
2,500.00
1,317.00
89.83%
Operating Profit Margin (Excl OI)
149.60%
95.20%
5.44%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - Aug'24
Aug'24
Aug'23
Change(%)
Net Sales
82,999.00
73,264.00
13.29%
Operating Profit (PBDIT) excl Other Income
10,763.00
7,765.00
38.61%
Interest
129.00
141.00
-8.51%
Exceptional Items
-773.00
-575.00
-34.43%
Consolidate Net Profit
4,671.00
1,762.00
165.10%
Operating Profit Margin (Excl OI)
94.40%
66.20%
2.82%
USD in Million.
Net Sales
YoY Growth in year ended Aug 2024 is 13.29% vs 9.51% in Aug 2023
Consolidated Net Profit
YoY Growth in year ended Aug 2024 is 165.10% vs 134.93% in Aug 2023
About Jins Holdings, Inc. 
Jins Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






